Avatar

Clinical Trials in Myeloma in 2018

By Krina Patel 4 Videos
06/2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
08:14
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
13:22
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

25:50
The University of Kansas Cancer Center

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
19:40
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

10:29
Society of Hematologic Oncology Sixth Annual Meeting

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
15:46
Society of Hematologic Oncology Sixth Annual Meeting

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
12:31
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

15:30
Parameswaran Hari

Refractory and Relapsing Myeloma - When to Treat and Options Available

13:29
Helen Heslop

CAR T-cell Therapy for Hematologic Malignancies Other Than CD19

09:45
2018 Pan Pacific Lymphoma Conference

CAR T-cell Toxicities and Team Management

Feat. S. Blumel
10:37
Krina Patel

How Do We Make Responses Durable in Multiple Myeloma?

17:57
City of Hope

Should Everyone Receive Monoclonal Antibodies at First Myeloma Relapse? No!

Feat. J. Mikhael
06:22
Parameswaran Hari

Treating Refractory & Relapsing Myeloma: Current Trends and Recommendati...

17:46
Dana-Farber Cancer Institute

Relapse Refractory Myeloma and Novel Treatments

Feat. N. Raje
09:00
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

14:42
Society of Hematologic Oncology Sixth Annual Meeting

What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?

Feat. R. Orlowski
11:50
C. Ola Landgren

Aiming for Minimal Residual Disease Negative Status in all Myeloma Patients

16:58
Nina Shah

The Future of CAR T Therapies in Myeloma in 2018